RxDoctor Payments Data

Jose Reyes, MD

Surgery · Hyannis, MANPI 1841455664

Payments from drug & device makers

$27,000in general payments, 2019–2025

Across 245 payments — averaging $110.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$21K
  • AbbVie$697
  • Procept Biorobotics Corporation$573
  • Johnson & Johnson$494
  • Sumitomo Pharma America, Inc.$477
  • Urogen Pharma, Inc.$354
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$19,72573%
  • Travel & lodging$7723%
  • Food & beverage$6,14623%
  • Education$3581%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,000 in reported general payments places this provider in the 90th percentile of 694 surgery providers in Massachusetts.

See all surgery providers in Massachusetts

Medicare billing

Part B allowed, 2024
$740,819
Medicare patients
1,515
Services billed
15,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron250$266,490
MyrbetriqMirabegron82$66,846
XyostedTestosterone Enanthate35$20,799
Tamsulosin Hcl863$19,534
Silodosin185$18,061
Methenamine Hippurate192$17,844
PremarinEstrogens, Conjugated34$14,862
Mirabegron ErMirabegron16$13,626
ElmironPentosan Polysulfate Sodium11$10,623
Finasteride479$7,482
Testosterone57$6,941
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl26$5,280
Dutasteride101$5,091
Tadalafil29$3,033
Fesoterodine Fumarate ErFesoterodine Fumarate23$2,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$477$266,490250 claims
Astellas Pharma US IncMyrbetriq$101$66,84682 claims
Antares Pharma, Inc.Xyosted$139$20,79935 claims
PfizerPremarin$275$14,86234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 surgery providers in Massachusetts.

Other surgery in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →